Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Can Intestinal Phosphate Binding or Inhibition of Hydroxyapatite Growth in the Vascular Wall Halt the Progression of Established Aortic Calcification in Chronic Kidney Disease?

Neven E, Opdebeeck B, De Maré A, Bashir-Dar R, Dams G, Marynissen R, Behets GJ, Verhulst A, Riser BL, D'Haese PC.

Calcif Tissue Int. 2016 Nov;99(5):525-534. Epub 2016 Jul 26.

PMID:
27461215
2.

Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.

Riser BL, Barnes JL, Varani J.

J Cell Commun Signal. 2015 Dec;9(4):327-39. doi: 10.1007/s12079-015-0309-3. Epub 2015 Dec 23.

3.

Peritoneal delivery of sodium pyrophosphate blocks the progression of pre-existing vascular calcification in uremic apolipoprotein-E knockout mice.

de Oliveira RB, Louvet L, Riser BL, Barreto FC, Benchitrit J, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Massy ZA.

Calcif Tissue Int. 2015 Aug;97(2):179-92. doi: 10.1007/s00223-015-0020-7. Epub 2015 Jun 19.

PMID:
26087714
4.

Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-β1, and vascular endothelial growth factor.

Abrahams AC, Habib SM, Dendooven A, Riser BL, van der Veer JW, Toorop RJ, Betjes MG, Verhaar MC, Watson CJ, Nguyen TQ, Boer WH.

PLoS One. 2014 Nov 10;9(11):e112050. doi: 10.1371/journal.pone.0112050. eCollection 2014.

5.

Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy.

Riser BL, Najmabadi F, Garchow K, Barnes JL, Peterson DR, Sukowski EJ.

Am J Pathol. 2014 Nov;184(11):2908-21. doi: 10.1016/j.ajpath.2014.07.009. Epub 2014 Sep 2.

PMID:
25193594
6.

Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease.

Barreto FC, de Oliveira RB, Benchitrit J, Louvet L, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Riser BL, Massy ZA.

J Bone Miner Metab. 2014 Nov;32(6):636-44. doi: 10.1007/s00774-013-0541-y. Epub 2014 Jan 21.

PMID:
24442863
7.

Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Riser BL, Bhagavathula N, Perone P, Garchow K, Xu Y, Fisher GJ, Najmabadi F, Attili D, Varani J.

J Cell Commun Signal. 2012 Jun;6(2):97-105. doi: 10.1007/s12079-012-0164-4. Epub 2012 May 31.

8.

Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia.

Riser BL, Barreto FC, Rezg R, Valaitis PW, Cook CS, White JA, Gass JH, Maizel J, Louvet L, Drueke TB, Holmes CJ, Massy ZA.

Nephrol Dial Transplant. 2011 Oct;26(10):3349-57. doi: 10.1093/ndt/gfr039. Epub 2011 Mar 11.

PMID:
21398365
9.

Treatment with pyrophosphate inhibits uremic vascular calcification.

O'Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL.

Kidney Int. 2011 Mar;79(5):512-7. doi: 10.1038/ki.2010.461. Epub 2010 Dec 1.

10.

CCN2 (CTGF) gene polymorphism is a novel prognostic risk factor for cardiovascular outcomes in hemodialysis patients.

Cozzolino M, Biondi ML, Banfi E, Riser BL, Mehmeti F, Cusi D, Gallieni M.

Blood Purif. 2010;30(4):272-6. doi: 10.1159/000320706. Epub 2010 Nov 11.

11.

CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.

Riser BL, Najmabadi F, Perbal B, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC, Peterson DR.

J Cell Commun Signal. 2010 Mar;4(1):39-50. doi: 10.1007/s12079-010-0085-z. Epub 2010 Feb 9.

12.

Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy.

Tam FW, Riser BL, Meeran K, Rambow J, Pusey CD, Frankel AH.

Cytokine. 2009 Jul;47(1):37-42. doi: 10.1016/j.cyto.2009.04.001. Epub 2009 May 5.

PMID:
19409809
13.

CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.

Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC.

Am J Pathol. 2009 May;174(5):1725-34. doi: 10.2353/ajpath.2009.080241. Epub 2009 Apr 9.

14.

Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF-beta1.

Haydont V, Riser BL, Aigueperse J, Vozenin-Brotons MC.

Am J Physiol Cell Physiol. 2008 Jun;294(6):C1332-41. doi: 10.1152/ajpcell.90626.2007. Epub 2008 Apr 9.

15.

TNF-alpha, but not IFN-gamma, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis.

Cooker LA, Peterson D, Rambow J, Riser ML, Riser RE, Najmabadi F, Brigstock D, Riser BL.

Am J Physiol Renal Physiol. 2007 Jul;293(1):F157-65. Epub 2007 Mar 20.

16.

Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report.

Riser BL, Cortes P, DeNichilo M, Deshmukh PV, Chahal PS, Mohammed AK, Yee J, Kahkonen D.

Kidney Int. 2003 Aug;64(2):451-8.

17.

Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria?

Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, LaPage J, Nast CC.

Am J Kidney Dis. 2002 Jul;40(1):184-8.

PMID:
12087577
18.

Putative subunits of the rat mesangial KATP: a type 2B sulfonylurea receptor and an inwardly rectifying K+ channel.

Szamosfalvi B, Cortes P, Alviani R, Asano K, Riser BL, Zasuwa G, Yee J.

Kidney Int. 2002 May;61(5):1739-49.

19.

Glomerular mRNAs in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy.

Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, LaPage J, Nast CC.

Kidney Int. 2001 Dec;60(6):2330-6. Erratum in: Kidney Int 2002 Mar;61(3):1197.

20.
21.
22.

F-actin fiber distribution in glomerular cells: structural and functional implications.

Cortes P, Méndez M, Riser BL, Guérin CJ, Rodríguez-Barbero A, Hassett C, Yee J.

Kidney Int. 2000 Dec;58(6):2452-61.

23.

Modelling the effects of vascular stress in mesangial cells.

Riser BL, Cortes P, Yee J.

Curr Opin Nephrol Hypertens. 2000 Jan;9(1):43-7. Review.

PMID:
10654824
24.

Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.

Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG.

J Am Soc Nephrol. 2000 Jan;11(1):25-38.

25.

TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain.

Riser BL, Ladson-Wofford S, Sharba A, Cortes P, Drake K, Guerin CJ, Yee J, Choi ME, Segarini PR, Narins RG.

Kidney Int. 1999 Aug;56(2):428-39.

26.

Mechanical strain of glomerular mesangial cells in the pathogenesis of glomerulosclerosis: clinical implications.

Cortes P, Riser BL, Yee J, Narins RG.

Nephrol Dial Transplant. 1999 Jun;14(6):1351-4.

PMID:
10382990
27.

Characterization of the rat mesangial cell type 2 sulfonylurea receptor.

Asano K, Cortes P, Garvin JL, Riser BL, Rodríguez-Barbero A, Szamosfalvi B, Yee J.

Kidney Int. 1999 Jun;55(6):2289-98.

28.

Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells.

Cortes P, Riser BL, Asano K, Rodríguez-Barbero A, Narins RG, Yee J.

Kidney Int. 1998 Dec;54(6):1985-98.

29.

Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-beta.

Riser BL, Cortes P, Yee J, Sharba AK, Asano K, Rodriguez-Barbero A, Narins RG.

J Am Soc Nephrol. 1998 May;9(5):827-36.

30.

Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy.

Cortes P, Zhao X, Riser BL, Narins RG.

Kidney Int. 1997 Jan;51(1):57-68.

31.

Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells.

Riser BL, Cortes P, Heilig C, Grondin J, Ladson-Wofford S, Patterson D, Narins RG.

Am J Pathol. 1996 Jun;148(6):1915-23.

32.

Regulation of glomerular volume in normal and partially nephrectomized rats.

Cortes P, Zhao X, Riser BL, Narins RG.

Am J Physiol. 1996 Feb;270(2 Pt 2):F356-70.

PMID:
8779898
33.

Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype.

Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P.

J Clin Invest. 1995 Oct;96(4):1802-14.

34.

Glomerular volume expansion and mesangial cell mechanical strain: mediators of glomerular pressure injury.

Cortes P, Riser BL, Zhao X, Narins RG.

Kidney Int Suppl. 1994 Feb;45:S11-6. Review. No abstract available.

PMID:
8158877
35.

Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat.

Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG.

J Clin Invest. 1992 Nov;90(5):1932-43.

37.

Thrombospondin binding by keratinocytes: modulation under conditions which alter thrombospondin biosynthesis.

Riser BL, Varani J, Nickoloff BJ, Mitra RS, Dixit VM.

Dermatologica. 1990;180(2):60-5.

PMID:
2107104
38.

Monocyte killing of human squamous epithelial cells: role for thrombospondin.

Riser BL, Mitra R, Perry D, Dixit V, Varani J.

Cancer Res. 1989 Nov 1;49(21):6123-9.

39.

Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells.

Varani J, Riser BL, Hughes LA, Carey TE, Fligiel SE, Dixit VM.

Clin Exp Metastasis. 1989 May-Jun;7(3):265-76.

40.

Production and utilization of extracellular matrix components by human melanocytes.

McClenic BK, Mitra RS, Riser BL, Nickoloff BJ, Dixit VM, Varani J.

Exp Cell Res. 1989 Feb;180(2):314-25.

42.

Inhibitory effect of gamma interferon on cultured human keratinocyte thrombospondin production, distribution, and biologic activities.

Nickoloff BJ, Riser BL, Mitra RS, Dixit VM, Varani J.

J Invest Dermatol. 1988 Sep;91(3):213-8.

43.

Thrombospondin-induced adhesion of human keratinocytes.

Varani J, Nickoloff BJ, Riser BL, Mitra RS, O'Rourke K, Dixit VM.

J Clin Invest. 1988 May;81(5):1537-44.

44.

Thrombospondin binding by human squamous carcinoma and melanoma cells: relationship to biological activity.

Riser BL, Varani J, O'Rourke K, Dixit VM.

Exp Cell Res. 1988 Feb;174(2):319-29.

45.
46.

Tissue destruction resulting from the interaction of cytotoxic T cells and their targets.

Steinmuller D, Tyler JD, Snider ME, Noble RL, Riser BL, Maassab HF, Galli SJ.

Ann N Y Acad Sci. 1988;532:106-18. Review.

47.

Phagocytosis of Candida albicans enhances malignant behavior of murine tumor cells.

Ginsburg I, Fligiel SE, Kunkel RG, Riser BL, Varani J.

Science. 1987 Dec 11;238(4833):1573-5.

PMID:
3317835
48.

Supplemental Content

Loading ...
Support Center